Tetrazole derivatives
US-2024382468-A2 · Nov 21, 2024 · US
Substituted indol-5-ol derivatives and their therapeutic applications
US10245261B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10245261-B2 |
| Application number | US-201615379696-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 15, 2016 |
| Priority date | Mar 15, 2013 |
| Publication date | Apr 2, 2019 |
| Grant date | Apr 2, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of substituted indol-5-ol derivatives to modulate protein kinases and for treating protein kinase-mediated diseases.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating cancer in a mammal, wherein the cancer is selected from the group consisting of Chronic Myelogenous Leukemia (CIVIL), Acute Myelogenous Leukemia (AML) and thyroid, endometrial, gastric, breast and pancreatic carcinoma, and wherein the method comprises administering to the mammal a therapeutically effective amount of a composition comprising NTW-3475, wherein NTW-3475 is the compound having the structure: 2. The method of claim 1 , wherein NTW-3475 is administered with other active agents. 3. The method of claim 1 , wherein NTW-3475 is administered with a carrier. 4. The method of claim 1 wherein the cancer is pancreatic carcinoma. 5. The method of claim 1 , wherein the administration of the composition results in reduced signal transduction by the pERK pathway. 6. The method of claim 1 , wherein the administration of the composition results in reduced signal transduction by the pERK pathway. 7. The method of claim 1 , wherein the mammal is human. 8. A method for reducing signal transduction by the pERK pathway in cells comprising contacting the cells with NTW-3475, wherein the cells are MiaPaCa-2 cells or BxPC3 cells, and wherein NTW-3475 is the compound having the structure: 9. The method of claim 8 , wherein the cells are in vivo. 10. The method of claim 8 , wherein the cells are human. 11. The method of claim 1 , wherein the cancer is CML. 12. The method of claim 1 , wherein the cancer is AML. 13. The method of claim 1 , wherein the cancer is thyroid carcinoma. 14. The method of claim 1 , wherein the cancer is endometrial carcinoma. 15. The method of claim 1 , wherein the cancer is gastric carcinoma. 16. The method of claim 1 , wherein the cancer is breast carcinoma.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Immunostimulants · CPC title
Drugs for immunological or allergic disorders · CPC title
Antihypertensives · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10245261B2 cover?
- The present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of substituted indol-5-ol derivatives to modulate protein kinases and for treating protein kinase-mediated diseases.
- Who is the assignee on this patent?
- Nantbioscience Inc, Nantbio Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D403/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).